| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 8, 2025 |
| Accession Number: | 0001193125-25-309605 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 8, 2025 |
| Accession Number: | 0001193125-25-309605 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/21/2026 | $75.00 | Buy | Guggenheim |
| 12/19/2025 | $38.00 | Overweight | Analyst |
| 8/27/2025 | $36.00 | Buy | Needham |
| 12/5/2023 | $30.00 | Buy | Chardan Capital Markets |
| 10/5/2023 | $35.00 | Buy | Stifel |
| 6/14/2023 | $22.00 | Buy | BofA Securities |
| 6/12/2023 | $28.00 | Buy | H.C. Wainwright |
| 6/8/2023 | $58.00 | Outperform | Robert W. Baird |
Oculis Holding AG claimed its "most important" drug, OSC-01, was biologically approved months before revealing the Phase 3 Diamond studies concerning the drug had failed to achieve their primary endpoints.NEW YORK, June 2, 2026 /PRNewswire/ -- Investors in Oculis Holding AG (NASDAQ:OCS) lost approximately 23.4% of their holdings in a single session after the company revealed that Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet the primary endpoint in diabetic macular edema. Shareholders who lost money on OCS are encouraged to submit their information now to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone
The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs vehicle in both trialsOculis will focus its developmental efforts and financial resources on the ongoing Privosegtor PIONEER registrational program in optic neuropathies and the Licaminlimab PREDICT-1 registrational trial in dry eye diseaseFinancial position remains strong with $278 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing cash runway into 2H 2029Conference call today at 4:30 pm ET ZUG, Switzerland, M
ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), today announced the results from its 2026 Annual General Meeting held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 12:00 p.m. CEST, including the election of Gregory D. Perry to its Board of Directors. 2026 Annual General Meeting Results The Company's shareholders approved all agenda items. The shareholders approved the 2025 Annual Report including the 2025 Annual (Statutory) Financial Statements and the 2025 Consolidated Financial Statements. The shareholders acknowledged that on a standalone statutory financial statement basis, the Company incur
6-K - Oculis Holding AG (0001953530) (Filer)
6-K - Oculis Holding AG (0001953530) (Filer)
SCHEDULE 13G/A - Oculis Holding AG (0001953530) (Subject)
Guggenheim initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $75.00
Analyst initiated coverage of Oculis Holding AG with a rating of Overweight and set a new price target of $38.00
Needham initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $36.00
ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis"), today published the invitation to the 2026 Annual General Meeting, which will be held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 6:00 a.m. EDT / 10:00 a.m. GMT / 12:00 p.m. CEST. The 2026 Annual General Meeting will be held in-person and broadcast, with no option for virtual participation. To join the broadcast, please use the following link: https://meetings.lumiconnect.com/100-352-684-319. Information pertaining to the 2026 Annual General Meeting, including meeting materials, can be accessed on our website at https://investors.oculis.com/events-pre
PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative long-term visual outcomes, significantly affecting function and quality of life Decision supported by positive Phase 2 ACUITY data showing substantial improvements in vision combined with anatomical and biological neuroprotective benefits in patients treated with Privosegtor Strong regulatory momentum bolsters the global development strategy, with PIONEER registrational program in optic neuropathies underway, potentially providing Privosegtor with an accelerated regulatory pathway ZUG, Switzerl
Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companiesChief Legal Officer (CLO) appointment enhances leadership capabilities to advance three highly differentiated late-stage assets toward near-term clinical and regulatory milestones ZUG, Switzerland, February 17, 2026 -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced the appointment of Katie Kazem as Chief Legal Officer, leading Oculis' le
Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAION Company to host conference call and webcast at 8:30 AM ET today ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant unmet medical needs, today announces the advancement of Privosegtor into a registrational program for neuro-ophtha
DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significancePrimary efficacy endpoint of mean change in Best Corrected Visual Acuity (BCVA) versus baseline at Week 6 showed statistically significant increase in visual acuity in the OCS-01 arm compared to vehicle armStatistically significant secondary endpoints showed higher percentage of patients achieving ≥15-letter improvement in BCVA and better improvement in retinal thickness in the OCS-01 arm versus vehicle armOCS-01 was well-tolerated with no unexpected adverse event
ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET. Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indica
SC 13G - Oculis Holding AG (0001953530) (Subject)
SC 13G/A - Oculis Holding AG (0001953530) (Subject)